NECLIFENSENectar Lifesciences Limited· PharmaceuticalsMediumNeutral
Announced Mon, 29 Sept · 16:45 IST

Nectar Lifesciences Limited has submitted the Exchange the outcome of Annual General Meeting held on September 29, 2025 with a copy Scrutinizer report, voting results and the new set of Articles of Association duly approved by the shareholders.

Board & Shareholder Meetings View source PDF

NECLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Nectar Lifesciences Limited held its 30th AGM on September 29, 2025, via video conferencing. All five resolutions were passed with overwhelming shareholder support, with approximately 99.93% of polled votes in favour on each resolution. Key items approved include: (1) adoption of standalone and consolidated financial statements for FY ended March 31, 2025; (2) re-appointment of Mr. Sanjiv Goyal (Managing Director and Promoter), who retires by rotation; (3) ratification of Cost Auditors' remuneration; (4) appointment of Mr. Prince Chadha of P. Chadha & Associates as Secretarial Auditor; and (5) approval of a new set of Articles of Association (a Special Resolution). Mr. Sanjiv Goyal holds 24.90% of shares directly and 19.45% as Karta of Sanjiv HUF, making him the single largest shareholder. Total shares outstanding stand at 22,426,097, with about 45.13% of total shares participating in the voting.

Likely market impact

This is a routine procedural filing with no material business impact. All resolutions passed with near-unanimous support, indicating strong shareholder alignment with management. The new Articles of Association and director re-appointment are administrative; no change in business direction or capital structure is signaled.